Evogene, Unravel Biosciences announce scientific collaboration

Evogene (EVGN) announced a scientific collaboration with Unravel Biosciences, a clinical-stage therapeutics company established to advance drugs for complex diseases through its Predictable Medicine platform. This partnership aims to accelerate the discovery and optimization of a first-in-class small-molecule therapeutic capable of restoring myelin and reversing neurological damage in demyelinating diseases. Evogene and Unravel have launched a joint effort to design and validate brain-penetrant inhibitors of a novel demyelination target discovered by Unravel’s platform and create the first therapeutic designed to restore myelin and improve neurological function. By taking a function-first discovery approach, the collaboration aims at gaining unique biological insights from genetically defined demyelinating disorders. Such insights will enable translating the discovered underlying biological mechanisms that drive reversal of demyelination to a plethora of such disorders, overcoming the challenge of restoring neurological function in patients.